Efficacy and Safety of Lumiracoxib in Patients With Primary Knee Osteoarthritis(OA)

Completed · Phase 3

Conditions studied: Osteoarthritis

In brief

This 39-week, open label study is designed to assess long-term efficacy, safety and tolerability of lumiracoxib 100mg od in patients with osteoarthritis (OA) of the knee who participated in the 13-week core CCOX189A2360 study.

Key facts

Study ID

NCT00475800

Run by

Novartis

People needed

833

Starts

2004-01-01

Last updated by the study team

2012-05-21

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Have completed the core CCOX189A2360 study
• Males and females over the 18 years old

You may not qualify if…

• Treatment in the extension study is not considered appropriate by the treating physician
• Non-compliance or major protocol violation of the core study
• Other protocol-defined inclusion/exclusion criteria may apply

Where it is running

• Study site — Tucson, Arizona, United States
• Study site — Brooklyn Park, Minnesota, United States
• Study site — Albuquerque, New Mexico, United States
• Study site — Sioux Falls, South Dakota, United States
• Study site — San Antonio, Texas, United States
• Novartis Investigative Site — Brampton, Ontario, Canada

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.